Sildenafil Tablet, Film Coated
Product Images NDC 51407-987

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 51407-987). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-987-90lb (Sildenafil Tablets 20g)

This text provides information about Sildenafil tablets, including dosage instructions, storage requirements, and contact details for GSMS, Incorporated. It also mentions details such as the GTIN, LOT number, expiration date, and NDC code for identification and tracking purposes. Additionally, the text emphasizes the importance of keeping medications out of reach of children and dispensing them in light-resistant containers.*

FDA Label Image

Fig-1 (Fig 1)

This text provides recommendations on how the drug fold change and 90% confidence intervals (CI) should be considered when interacting with different medications. It includes information on drugs such as Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir and mentions whether dose adjustment or coadministration is recommended. Additionally, it highlights that there is no benefit on exercise capacity when adding sildenafil to bosentan therapy.*

FDA Label Image

Fig08 (Fig08)

Interacting Drug Fold Change and 90%CI Recommendation: This text provides a list of drugs with corresponding recommendations for dose adjustments based on various parameters such as INR, AUC, Cmax, and clinical studies. Some drugs like Acenocoumarol, Aspirin, Atorvastatin, and Levonorgestel do not require dose adjustments with interacting drugs. However, drugs like Ritonavir may have interactions with other drugs and are not recommended for coadministration. The text also mentions specific doses for drugs like Doxazosin and Sildenafil, with additional information related to bleeding time and exercise capacity.*

FDA Label Image

Fig09 (Fig09)

This text appears to be showing changes in distance measurements (in meters) over the course of a study involving different dosages of a medication called sildenafil. The dosages mentioned are 20 mg three times a day (TID), 40 mg TID, and 80 mg TID. The changes in distance from the baseline are being monitored at week 8 and week 12 of the study.*

FDA Label Image

Fig10 (Fig10)

This text seems to be a clinical data summary for a patient being treated with sildenafil (20 mg three times a day) for idiopathic pulmonary arterial hypertension (PAH) of various etiologies like PAH-CTD or PAH post-surgical repair. The data includes baseline walk distance, functional capacity assessment using the WHO Functional Class system, gender distribution, age distribution, mean pulmonary arterial pressure (PAP), and changes in 6-minute walk distance with placebo correction. This information appears to be part of a study or review evaluating the efficacy of sildenafil in patients with PAH.*

FDA Label Image

Fig11 (Fig11)

This text seems to provide data related to the effect of a placebo compared to sildenafil over several days from randomization. The numbers possibly represent outcomes or measurements over time.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.